SCHEMBL4501138

SCHEMBL4501138

O=C1N(Cc2ccccc2)CCN1Cc1c(Cl)cccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.59
CYP2C19 P33261 2/20 0.59
KMT2A Q03164 2/20 0.59
POLB P06746 2/20 0.59
CYP2C9 P11712 1/20 0.59
DRD3 P35462 5/20 0.54
KCNH2 Q12809 5/20 0.54
CYP3A4 P08684 2/20 0.54
CYP1A2 P05177 1/20 0.54
DRD2 P14416 2/20 0.49
HPGD P15428 1/20 0.49
MEN1 O00255 1/20 0.48
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
SIGMAR1 Q99720 1/20 0.47
NPSR1 Q6W5P4 2/20 0.47
RECQL P46063 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
TP53 P04637 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4513935 0.91 CYP2D6 (0.53) CYP2D6CYP2C19KMT2APOLBCYP2C9
SCHEMBL4516856 0.86 P2RX7 (0.46) CYP2D6CYP2C19KMT2APOLBCYP2C9
SCHEMBL29450073 0.86 KMT2A (0.76) CYP2D6CYP2C19KMT2APOLBCYP2C9
SCHEMBL16416392 0.86 KMT2A (0.76) CYP2D6CYP2C19KMT2APOLBCYP2C9
SCHEMBL4503325 0.83 CYP2D6 (0.74) CYP2D6CYP2C19KMT2APOLBCYP2C9
SCHEMBL4510323 0.82 P2RX7 (0.51) CYP2D6CYP2C19POLBDRD3KCNH2
SCHEMBL4517648 0.81 KDM4E (0.46) KMT2APOLBKCNH2MEN1KDM4E
SCHEMBL4515866 0.81 HPGD (0.51) CYP2D6CYP2C19KMT2APOLBCYP2C9
SCHEMBL4516861 0.80 CYP2D6 (0.58) CYP2D6CYP2C19KMT2APOLBCYP2C9
SCHEMBL4510232 0.80 P2RX7 (0.58) CYP2D6CYP2C19KMT2ADRD3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 CYP2D6 469/4885CYP2C19 304/4885KMT2A 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.